Exposure-response analyses for tafenoquine after administration to patients with Plasmodium vivax malaria

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6188-6194

  Tenero, David ^a   Green, Justin A ^b   Goyal, Navin ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; PRIMAQUINE; TAFENOQUINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT;

ABSORPTION LAG TIME; ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; ORAL CLEARANCE; PARALLEL DESIGN; PARASITE CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE; DRUG EFFECTS; MALARIA, VIVAX; PARASITOLOGY; PATHOGENICITY; PLASMODIUM VIVAX; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AMINOQUINOLINES; ANTIMALARIALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX; YOUNG ADULT;

EID: 84942852203     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00718-15     Document Type: Article

References (12)

1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77(Suppl 6):79-87.
2. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. Eur J Med Chem 44:937-953. http://dx.doi.org/10.1016/j.ejmech.2008.08.011.
3. WHO. 2010. Guidelines for the treatment of malaria, 2nd ed. WHO, Geneva, Switzerland.
4. Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG, Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK, Schuster BG, Horton J, Braitman DJ, Brueckner RP. 1999. Randomized dose-ranging study of the safety and efficacy of WR238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 180:1282-1287. http://dx.doi.org/10.1086/315034.
5. Walsh DS, Wilairatana P, Tang DB, Heppner DG, Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S. 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 39:1095-1103. http://dx.doi.org/10.1086/424508.
6. Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R. 2001. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 33:1968-1974. http://dx.doi.org/10.1086/324081.
7. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. 1998. First-time-inhuman safety and pharmacokinetics of WR238605, a new antimalarial. Am J Trop Med Hyg 58:645-649.
8. Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C. 2011. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected rhesus monkeys (Macaca mulatta). Malar J 10:212. http://dx.doi.org/10.1186/1475-2875-10-212.
9. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L. 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383:1049-1058. http://dx.doi.org/10.1016/S0140-6736 (13) 62568-4.
10. Rueangweerayut R, Bancone G, Beelan A, Carter N, Duparc S, Green J, Harrell E, Kleim JP, Miller A, Möhrle J, Qureshi A, Yubon N, Luzzatto L, Nosten F, Kongpatanakul S. 2012. A phase I study to investigate the haemolytic potential of tafenoquine in healthy subjects with glucose-6-phosphate dehydrogenase deficiency (TAF110027). Abstr 61st Annual Meet Am Soc Trop Med Hyg, abstr 435.
11. White NJ. 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10:297. http://dx.doi.org/10.1186/1475-2875-10-297.
12. Tarning J, Chotsiri P, Jullien V, Rijken MJ, Bergstrand M, Cammas M, McGready R, Singhasivanon P, Day NP, White NJ, Nosten F, Lindegardh N. 2012. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother 56:5764-5773. http://dx.doi.org/10.1128/AAC.01242-12.